Who are Abelmoschus manihot (AM)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): XueBiJing Injection, Compound Kushen Injection（CKI）.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abelmoschus-manihot-am.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Abelmoschus manihot (AM) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Abelmoschus manihot (AM) (Abelmoschus manihot (AM)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Herbal extract / Traditional Chinese Medicine. Area: Nephrology.

marketed Herbal extract / Traditional Chinese Medicine Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

Abelmoschus manihot (AM) (Abelmoschus manihot (AM)) — Chinese PLA General Hospital. Abelmoschus manihot is a herbal extract that reduces proteinuria and inflammation in kidney disease through antioxidant and anti-inflammatory pathways.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Abelmoschus manihot (AM) TARGET	Abelmoschus manihot (AM)	Chinese PLA General Hospital	marketed	Herbal extract / Traditional Chinese Medicine
XueBiJing Injection	XueBiJing Injection	Nanjing Medical University	marketed	Herbal extract / Traditional Chinese Medicine
Compound Kushen Injection（CKI）	Compound Kushen Injection（CKI）	Shanxi Zhendong Pharmacy Co., Ltd	marketed	Herbal extract / Traditional Chinese medicine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Herbal extract / Traditional Chinese Medicine class)

Chinese PLA General Hospital · 1 drug in this class
Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Abelmoschus manihot (AM) — Competitive Intelligence Brief. https://druglandscape.com/ci/abelmoschus-manihot-am. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing